Tesaro (NASDAQ:TSRO) tumbled almost 25% on Monday as investors question its ability to differentiate its drug for chemotherapy induced nausea and vomiting (CINV) from existing NK-1 antagonists after missing secondary endpoints in two phase III trials. Rolapitant achieved the primary endpoint of complete response (CR) in the delayed period (24-120 hours) following initiation of chemotherapy in both a highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). The missed secondary endpoints were overall complete response (0-120 hours) and acute complete response (0-24 hours). We believe the stock price movement is an overreaction and presents a buying opportunity for speculative, patient investors with over 100% potential upside versus 26% potential downside over the next 24 months.
Our investment premise...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|